Cargando…

Recent Advances in the Development of Nanodelivery Systems Targeting the TRAIL Death Receptor Pathway

The TRAIL (TNF-related apoptosis-inducing ligand) apoptotic pathway is extensively exploited in the development of targeted antitumor therapy due to TRAIL specificity towards its cognate receptors, namely death receptors DR4 and DR5. Although therapies targeting the TRAIL pathway have encountered ma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yagolovich, Anne V., Gasparian, Marine E., Dolgikh, Dmitry A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961178/ https://www.ncbi.nlm.nih.gov/pubmed/36839837 http://dx.doi.org/10.3390/pharmaceutics15020515

Ejemplares similares

Death Receptors DR4 and DR5 Undergo Spontaneous and Ligand-Mediated Endocytosis and Recycling Regardless of the Sensitivity of Cancer Cells to TRAIL
por: Artykov, Artem A., et al.
Publicado: (2021)

Corrigendum: Death Receptors DR4 and DR5 Undergo Spontaneous and Ligand-Mediated Endocytosis and Recycling Regardless of the Sensitivity of Cancer Cells to TRAIL
por: Artykov, Artem A., et al.
Publicado: (2022)

Optimized Heterologous Expression and Efficient Purification of a New TRAIL-Based Antitumor Fusion Protein SRH–DR5-B with Dual VEGFR2 and DR5 Receptor Specificity
por: Yagolovich, Anne V., et al.
Publicado: (2022)

Combination of TRAIL with Bortezomib Shifted Apoptotic Signaling from DR4 to DR5 Death Receptor by Selective Internalization and Degradation of DR4
por: Bychkov, Maxim L., et al.
Publicado: (2014)

Doxorubicin-Loaded Polyelectrolyte Multilayer Capsules Modified with Antitumor DR5-Specific TRAIL Variant for Targeted Drug Delivery to Tumor Cells
por: Gileva, Anastasia, et al.
Publicado: (2023)

Genetically Modified DR5-Specific TRAIL Variant DR5-B Revealed Dual Antitumor and Protumoral Effect in Colon Cancer Xenografts and an Improved Pharmacokinetic Profile
por: Yagolovich, Anne V., et al.
Publicado: (2020)

Chemotherapeutic Agents Sensitize Resistant Cancer Cells to the DR5-Specific Variant DR5-B More Efficiently Than to TRAIL by Modulating the Surface Expression of Death and Decoy Receptors
por: Artykov, Artem A., et al.
Publicado: (2020)

Amphiphilic Poly(N-vinylpyrrolidone) Nanoparticles Conjugated with DR5-Specific Antitumor Cytokine DR5-B for Targeted Delivery to Cancer Cells
por: Yagolovich, Anne, et al.
Publicado: (2021)

Recent Advances and Challenges in Nanodelivery Systems for Antimicrobial Peptides (AMPs)
por: Tang, Ziyan, et al.
Publicado: (2021)

DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma
por: Yagolovich, Anne V., et al.
Publicado: (2022)

Nanodelivery Systems Targeting Epidermal Growth Factor Receptors for Glioma Management
por: Paranthaman, Sathishbabu, et al.
Publicado: (2020)

Therapeutic targeting of TRAIL death receptors
por: Di Cristofano, Francesca, et al.
Publicado: (2023)

Development of a liposomal nanodelivery system for nevirapine
por: Ramana, Lakshmi N, et al.
Publicado: (2010)

mRNA nanodelivery systems: targeting strategies and administration routes
por: Yuan, Mujie, et al.
Publicado: (2023)

Actively Targeted Nanodelivery of Echinomycin Induces Autophagy-Mediated Death in Chemoresistant Pancreatic Cancer In Vivo
por: Thomas, Alexandra, et al.
Publicado: (2020)

Advances in Nanodelivery of Green Tea Catechins to Enhance the Anticancer Activity
por: Jiang, Yike, et al.
Publicado: (2021)

Targeting Death Receptor TRAIL-R2 by Chalcones for TRAIL-Induced Apoptosis in Cancer Cells
por: Szliszka, Ewelina, et al.
Publicado: (2012)

Nanodelivery systems: An efficient and target‐specific approach for drug‐resistant cancers
por: Ashique, Sumel, et al.
Publicado: (2023)

Nanodelivery of a functional membrane receptor to manipulate cellular phenotype
por: Patriarchi, Tommaso, et al.
Publicado: (2018)

Epigallocatechin Gallate Nanodelivery Systems for Cancer Therapy
por: Granja, Andreia, et al.
Publicado: (2016)

Therapeutic Potential of Epigallocatechin Gallate Nanodelivery Systems
por: Granja, Andreia, et al.
Publicado: (2017)

Microfluidization trends in the development of nanodelivery systems and applications in chronic disease treatments
por: Ganesan, Palanivel, et al.
Publicado: (2018)

Chitosan-based nanodelivery systems applied to the development of novel triclabendazole formulations
por: Real, Daniel, et al.
Publicado: (2018)

Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking
por: Conniot, João, et al.
Publicado: (2014)

A novel small peptide as an epidermal growth factor receptor targeting ligand for nanodelivery in vitro
por: Han, Cui-yan, et al.
Publicado: (2013)

TRAIL Induces Nuclear Translocation and Chromatin Localization of TRAIL Death Receptors
por: Mert, Ufuk, et al.
Publicado: (2019)

Nanodelivery of Dietary Polyphenols for Therapeutic Applications
por: Rudrapal, Mithun, et al.
Publicado: (2022)

Nanodelivery of antiretroviral drugs to nervous tissues
por: Lawal, Sodiq Kolawole, et al.
Publicado: (2022)

A Carrier-Free Folate Receptor-Targeted Ursolic Acid/Methotrexate Nanodelivery System for Synergetic Anticancer Therapy
por: Lan, Jin-Shuai, et al.
Publicado: (2021)

Nanodelivery Systems as New Tools for Immunostimulant or Vaccine Administration: Targeting the Fish Immune System
por: Ji, Jie, et al.
Publicado: (2015)

Engineered Nanodelivery Systems to Improve DNA Vaccine Technologies
por: Lim, Michael, et al.
Publicado: (2020)

Overcoming Multidrug Resistance of Antibiotics via Nanodelivery Systems
por: Imran, Mohammad, et al.
Publicado: (2022)

Exploring the Potential of Cannabinoid Nanodelivery Systems for CNS Disorders
por: Kolesarova, Mariana, et al.
Publicado: (2023)

Quantitative Characterization of Olaparib in Nanodelivery System and Target Cell Compartments by LC-MS/MS
por: Ottria, Roberta, et al.
Publicado: (2019)

Tristetraprolin Posttranscriptionally Downregulates TRAIL Death Receptors
por: Lee, Won Hyeok, et al.
Publicado: (2020)

Glucose oxidase and metal catalysts combined tumor synergistic therapy: mechanism, advance and nanodelivery system
por: Fu, Yuhan, et al.
Publicado: (2023)

Nanodelivery of Natural Antioxidants: An Anti-aging Perspective
por: Vaiserman, Alexander, et al.
Publicado: (2020)

Image-Guided Nanodelivery of Pt(IV) Prodrugs to GRP-Receptor Positive Tumors
por: Silva, Francisco, et al.
Publicado: (2023)

The Combination of TRAIL Treatment and Cancer Cell Selective Expression of TRAIL-Death Receptor DR4 Induces Cell Death in TRAIL-Resistant Cancer Cells
por: Choi, Eunah, et al.
Publicado: (2006)

Exosomes as a Nanodelivery System: a Key to the Future of Neuromedicine?
por: Aryani, Arian, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ig7ainqv84hc2vcu1l5k47qi2a